整合驱动基因的胰腺癌术后生存预测模型
本研究基于2018至2023年接受根治性胰腺切除术的胰腺导管腺癌患者,构建整合KRAS、TP53、SMAD4和CDKN2A驱动基因突变与临床病理变量的Cox模型预测总生存。663例患者中位随访40.8个月,驱动基因突变累积负担是独立预后因素(每突变HR 1.27,P<0.001),整合模型C-index 0.690,显著优于AJCC第八版病理分期(C-index 0.568)。
要点
- 驱动基因突变累积数量与术后总生存独立相关,每增加一个突变HR 1.27。
- 整合基因组与临床病理变量的模型区分度C-index 0.690,优于AJCC分期0.568。
- 模型需外部验证后方可用于临床决策。
核心结论
- 驱动基因突变累积负担为胰腺导管腺癌切除术后提供独立且增量的预后信息。
- 整合模型区分度中等且显著优于AJCC第八版病理分期,但临床使用前需外部验证。
研究设计与样本
- 基于2018至2023年前瞻性维护的胰腺切除术数据库,纳入接受根治性切除的PDAC患者。
- 检测KRAS、TP53、SMAD4和CDKN2A体细胞突变,采用限制性立方样条评估非线性效应。
- 构建整合基因组与临床病理变量的Cox比例风险模型预测总生存,并使用1000次bootstrap重抽样验证。
主要发现
- 共识别885例患者,其中663例符合纳入标准。
- 中位随访40.8个月,387例死亡,中位总生存28.4个月。
- 1年、2年和3年总生存率分别为80.0%、56.2%和41.5%。
- 单变量分析中KRAS、TP53、SMAD4和CDKN2A突变均与较差总生存相关。
- 多变量分析中驱动基因突变累积数量(0-4)每增加一个突变HR 1.27(P<0.001),保持独立显著。
关键数值与推荐
- 其他独立总生存预测因素包括高龄、可切除性状态、治疗前CA19-9升高、较大肿瘤尺寸、淋巴结分期阳性、淋巴血管侵犯、低分化、新辅助治疗反应分类和接受辅助化疗。
- 整合模型C-index为0.690(95%CI 0.669至0.723),乐观校正后C-index为0.676。
- AJCC第八版病理分期单独C-index为0.568(95%CI 0.545至0.599),ΔC=0.122,P<0.001。
- 整合模型校准度合理。
临床怎么用
- 对于接受根治性切除的PDAC患者,可结合驱动基因突变累积数量与临床病理因素进行术后生存风险评估。
- 该模型目前尚不能直接用于临床决策,需等待外部验证。
局限性
- 模型需外部验证后方可临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to develop an overall survival (OS) prediction model integrating key somatic driver gene mutations in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing curative-intent pancreatectomy. METHODS: Patients with resected PDAC from a prospectively maintained pancreatectomy database from 2018 to 2023 were identified. Somatic mutations in KRAS, TP53, SMAD4, and CDKN2A were assessed using in-house or commercial sequencing panels. Restricted cubic spline analyses were used to assess non-linear effects. An integrated Cox proportional hazards model incorporating genomic and clinicopathological variables was developed to predict OS and validated using 1000 bootstrap resamples. RESULTS: In total, 885 patients were identified, of whom 663 met the inclusion criteria. After a median follow-up of 40.8 months, 387 deaths occurred (median OS of 28.4 months). The 1-, 2-, and 3-year OS rates were 80.0%, 56.2%, and 41.5% respectively. In univariable analysis, mutations in KRAS, TP53, SMAD4, and CDKN2A were each associated with inferior OS. Mortality risk increased with the cumulative number of mutated driver genes and remained independently significant in multivariable analysis (0-4; HR per mutation 1.27; P < 0.001). Other independent OS predictors included advanced age, resectability status, elevated pretreatment carbohydrate antigen 19-9 (CA19-9), larger tumour size, positive nodal stage, lymphovascular invasion, poor differentiation, neoadjuvant response classification, and receipt of adjuvant chemotherapy. The integrated model showed moderate discrimination (C-index 0.690 (95% c.i. 0.669 to 0.723); optimism-corrected C-index 0.676), which was significantly higher than AJCC eighth edition pathological staging alone (C-index 0.568 (95% c.i. 0.545 to 0.599); ΔC = 0.122; P < 0.001), with reasonable calibration. CONCLUSION: The cumulative burden of driver gene mutations provided independent and incremental prognostic information after PDAC resection. External validation is required before clinical application.
引用
- Li Z, Campbell BA, Molin MD, et al. Integrated driver gene-based survival prediction in resected pancreatic cancer. Br J Surg. 2026. PMID: 42809368. doi:10.1093/bjs/znag123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。